In the October issue of the internationally renowned interdisciplinary journal IntegratIve BIology, Professor Huang Laiqiang and his team's latest academic achievements in the field of anticancer drugs became cover articles in the Department of Life and Health of the Shenzhen Graduate School of Tsinghua University.
The treatment of breast cancer is more effective. In this study, Professor Huang Laiqiang and his student, the team of 8 young people led by Tsinghua's associate professor Mei Lin, designed and successfully synthesized a new type of biodegradable copolymer. The excellent nano-anticancer drug preparation materials are pharmaceutical excipients. Experimental studies on breast cancer cells and mouse animal models showed that the nano-polydtaxane preparations made from this copolymer have more significant cancer treatment effects than the current clinically used docetaxel preparation, Taxol Diester. Good clinical application and industrialization prospects.
The judges of the international peer authority experts organized by IntegratIve BIology conducted a rigorous review of the results and highly evaluated the results. The paper finally appeared on the Internet in the form of an electronic version on September 22. The paper version of the publication was formally published in October. Surprisingly, "IntegratIve BIology", which has always been known for its "picking", made this paper a cover article and made a special recommendation titled "Copolymer Nanoparticles Targeting Breast Cancer."
Huang Laiqiang's research team has made great achievements. Professor Huang Laiqiang, a senior research scientist at Stanford University Medical School and senior scientist at Silicon Valley Biopharmaceutical Company, has a brilliant resume. In 2003, he gave up his superior business and living conditions. He was hired as a leader in life science biomedicine at the Shenzhen Graduate School of Tsinghua University, established a biomedical research center, and set up a key laboratory for gene and antibody treatment in Shenzhen in 2007.
Under the leadership of Huang Laiqiang, the laboratory aims at the frontiers of related disciplines, adopting genes/RNAs, antibodies/polypeptides, stem cells, and means of cross-convergence with nanotechnology, and focuses on the treatment of neoplastic diseases including cervical cancer and liver cancer. And technologies and their molecular cellular mechanisms. This method of cross-cutting is still at the forefront of the world.
The treatment of breast cancer is more effective. In this study, Professor Huang Laiqiang and his student, the team of 8 young people led by Tsinghua's associate professor Mei Lin, designed and successfully synthesized a new type of biodegradable copolymer. The excellent nano-anticancer drug preparation materials are pharmaceutical excipients. Experimental studies on breast cancer cells and mouse animal models showed that the nano-polydtaxane preparations made from this copolymer have more significant cancer treatment effects than the current clinically used docetaxel preparation, Taxol Diester. Good clinical application and industrialization prospects.
The judges of the international peer authority experts organized by IntegratIve BIology conducted a rigorous review of the results and highly evaluated the results. The paper finally appeared on the Internet in the form of an electronic version on September 22. The paper version of the publication was formally published in October. Surprisingly, "IntegratIve BIology", which has always been known for its "picking", made this paper a cover article and made a special recommendation titled "Copolymer Nanoparticles Targeting Breast Cancer."
Huang Laiqiang's research team has made great achievements. Professor Huang Laiqiang, a senior research scientist at Stanford University Medical School and senior scientist at Silicon Valley Biopharmaceutical Company, has a brilliant resume. In 2003, he gave up his superior business and living conditions. He was hired as a leader in life science biomedicine at the Shenzhen Graduate School of Tsinghua University, established a biomedical research center, and set up a key laboratory for gene and antibody treatment in Shenzhen in 2007.
Under the leadership of Huang Laiqiang, the laboratory aims at the frontiers of related disciplines, adopting genes/RNAs, antibodies/polypeptides, stem cells, and means of cross-convergence with nanotechnology, and focuses on the treatment of neoplastic diseases including cervical cancer and liver cancer. And technologies and their molecular cellular mechanisms. This method of cross-cutting is still at the forefront of the world.
The natural ginger we supply comes from the best origin ,the quality of the natural ginger also is the best, price of the natural ginger we supply is competitive.The variety of the natural ginger we can according to your requirement.
1. Commodity Name: Natural Ginger
2. Feature: Shiny yellow color, plump, clean, smooth, no pests or rotten3. Size: 50g,100g, 150g, 200g,250g, 300g, 350g & up
4. Variety: Fresh Ginger
5. Packing:
a) calcium plastic carton: 30lbs/ctn, 10lbs/ctn
b) paper carton: 10kg/ctn, 20kg/ctn with plastic bag inner
c) mesh bag: 10kg/bag, 20kg/bag
d) or according to clients' requirements.
6. Supply Period: all Year Round
7. Conveyance: 22-27MT/40' HR( loading quantity depending on packing)
8.Transporting and storing temperature: +13°C
Natural Ginger,Natural Organic Ginger,Natural Mature Ginger,Natural Fresh Ginger
JINING FORICH FRUITS & VEGETABLES CO., LTD. , https://www.forichgarlic.com